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Minimally Elevated Cardiac Troponin T
and Elevated N-Terminal Pro-B-Type
Natriuretic Peptide Predict Mortality in Older Adults
Results From the Rancho Bernardo Study
Lori B. Daniels, MD, MAS,* Gail A. Laughlin, PHD,† Paul Clopton, MS,*‡
Alan S. Maisel, MD, FACC,*‡ Elizabeth Barrett-Connor, MD†
San Diego and La Jolla, California
Objectives This study investigated the prognostic value of detectable cardiac troponin T (TnT) and elevated N-terminal pro-B-
type natriuretic peptide (NT-proBNP) levels in a population of community-dwelling older adults.
Background Minimally elevated levels of TnT, a marker of cardiomyocyte injury, have been found in small subsets of the general
population, with uncertain implications. A marker of ventricular stretch, NT-proBNP has clinical utility in many venues,
but its long-term prognostic value in apparently healthy older adults and in conjunction with TnT is unknown.
Methods Participants were 957 older adults from the Rancho Bernardo Study with plasma NT-proBNP and TnT measured
at baseline (1997 to 1999) and followed up for mortality through July 2006.
Results Participants with detectable TnT (0.01 ng/ml, n  39) had an increased risk of all-cause and cardiovascular
death (adjusted hazard ratio [HR] by Cox proportional hazards analysis: 2.06; 95% confidence interval [CI]: 1.29
to 3.28, p  0.003 for all-cause mortality; HR: 2.06, 95% CI: 1.03 to 4.12, p  0.040 for cardiovascular mortal-
ity); elevated NT-proBNP also predicted an increased risk of all-cause and cardiovascular mortality (adjusted HR
per unit-log increase in NT-proBNP: 1.85, 95% CI: 1.36 to 2.52, p  0.001 for all-cause mortality; HR: 2.51, 95%
CI: 1.55 to 4.08, p  0.001 for cardiovascular mortality). Those with both elevated NT-proBNP and detectable
TnT had poorer survival (HR for high NT-proBNP and detectable TnT vs. low NT-proBNP and any TnT: 3.20, 95%
CI: 1.91 to 5.38, p  0.001). Exclusion of the 152 participants with heart disease at baseline did not materially
change the TnT mortality or NT-proBNP mortality associations.
Conclusions Apparently healthy adults with detectable TnT or elevated NT-proBNP levels are at increased risk of death. Those
with both TnT and NT-proBNP elevations are at even higher risk, and the increased risk persists for
years. (J Am Coll Cardiol 2008;52:450–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.033t
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pardiac troponin T (TnT) and N-terminal pro-B-type
atriuretic peptide (NT-proBNP) are two distinct biomar-
ers that have both emerged as valuable tools in confirming
rom the *Division of Cardiology, Department of Medicine, University of California
t San Diego, San Diego, California; †Department of Family and Preventive
edicine, University of California at San Diego, San Diego, California; and the
Veteran’s Affairs San Diego Healthcare System, La Jolla, California. The Rancho
ernardo Study was funded by research grants AG07181 and AG028507 from the
ational Institute on Aging and grant DK31801 from the National Institute of
iabetes and Digestive and Kidney Diseases. This work was also supported by grants
rom the American Heart Association Western States Affiliate (Dr. Daniels) and from
he American College of Cardiology/Guidant Foundation (Dr. Daniels). Roche
iagnostics, Inc. supplied the reagents for analyzing the biomarkers for this report but
ad no input into data acquisition, data analysis, manuscript preparation, or any other
spect of the study. Drs. Maisel and Daniels have received research grants from Roche
iagnostics. The investigators had full access to the data and take responsibility for
ts integrity. All investigators have read and agree to the article as written. Christopher
annon, MD, served as Guest Editor for this article.a
Manuscript received January 18, 2008; revised manuscript received April 23, 2008,
ccepted April 27, 2008.he diagnosis of cardiovascular disease (CVD) during the
ast decade. Cardiac TnT is a protein expressed by cardiac
yocytes and released in the setting of myocardial injury. A
ensitive and specific marker of myocardial injury, TnT is
sed clinically in the diagnosis of myocardial infarction.
levations of TnT seen in acute coronary settings have helped
uide risk stratification, prognosis, and therapeutic manage-
ent (1–6) and have long-term prognostic value when present
ven months after an acute coronary syndrome (7). However,
nT levels can also be elevated and clinically meaningful in the
bsence of clinically suspected myocardial ischemia. For exam-
le, in the setting of disease states such as heart failure and
hronic renal failure, even small elevations of TnT are associ-
ted with a poor prognosis (8–11). Minimally elevated levels of
nT have also been found in small subsets of the general
opulation; the cause and significance of these rare elevations
re unclear, but it seems to portend a worse prognosis (12,13).
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August 5, 2008:450–9 TnT and NT-proBNP Predict MortalityNatriuretic peptides are secreted from cardiac myocytes in
esponse to ventricular wall stretch (14). The precursor
rotein is cleaved into the biologically active B-type natri-
retic peptide (BNP) and the inactive N-terminal frag-
ent (NT-proBNP), both of which have been shown to be
seful in detecting abnormal ventricular function (15,16)
nd in diagnosing heart failure (17,18) in symptomatic
atients. They also provide prognostic information in the
etting of acute coronary syndromes (5,6,19,20), heart
ailure (21–23), and a variety of other settings (24–27).
merging data suggest that natriuretic peptides may also be
seful in screening asymptomatic populations for subclinical
VD (28–30).
The purpose of this study was to investigate the prog-
ostic utility of minimally detectable TnT levels along with
levated NT-proBNP levels in predicting clinical outcomes
n a population of community-dwelling older adults.
ethods
tudy population. The Rancho Bernardo Study is a pro-
pective, population-based study of the epidemiology of
hronic disease in older adults. Between 1972 and 1974, all
ommunity-dwelling residents ages 30 to 79 years of Rancho
ernardo, a community in Southern California, were in-
ited to participate in a study of heart disease risk factors,
nd 82% (n  5,052) enrolled. Nearly all were Caucasian,
iddle to upper-middle class, and relatively well-educated.
he present analysis consists of the 957 of 1,096 surviving,
ocally resident participants who attended a study visit
etween 1997 and 1999, and who had frozen plasma
vailable for analysis in 2006. One of the 957 participants
ad insufficient plasma available for measurement of TnT;
ll others had both TnT and NT-proBNP measured.
ompared with the 139 individuals without NT-proBNP
easured, the 957 participants studied were somewhat older
nd had a slightly higher prevalence of diabetes, hyperten-
ion, and cardiovascular disease, but did not differ by
ender, body mass index (BMI), or lipid levels. All partic-
pants gave written informed consent, and the study proto-
ol was approved by the human research protection program
t the University of California at San Diego (La Jolla,
alifornia).
ata collection. Baseline data for these analyses were
ollected at the 1997 to 1999 Rancho Bernardo Study
esearch clinic visit and included demographics, medical
istory (including history of cardiovascular events and re-
ascularization procedures), and life-style information. His-
orical data and information on physical activity (exercise 3
r more times per week, yes or no), alcohol consumption (3
r more drinks per week vs. less or none), and current
moking (yes or no) were obtained using standard question-
aires developed by the Rancho Bernardo Research Group.
urrent medication use was validated by examination of
ills and prescriptions brought to the clinic for that purpose.
lood pressure was measured in seated, resting subjects dsing the Hypertension Detec-
ion and Follow-up Program
rotocol (31); the mean of 2
eadings was used in analyses.
he BMI (kg/m2) was derived
rom height and weight mea-
ured in the clinic with partici-
ants wearing light clothing and
o shoes. Diabetes mellitus was
efined as a fasting plasma glu-
ose level 126 mg/dl, reported
hysician diagnosis, or use of
iabetes medications. Hyperten-
ion was defined as use of anti-
ypertensive medications, or rest-
ng blood pressure 140 mm Hg
ystolic or 90 mm Hg diastolic.
stimated creatinine clearance
eCrCl) was calculated using the
ockroft-Gault formula [creati-
ine clearance (ml/min)  weight (kg)  (140  age)/
creatinine (mg/dl) 72) 0.85 (if female)], which may be
ore accurate than the Modification of Diet in Renal
isease equation in subjects with near-normal glomerular
ltration rates (32,33). Participants were followed up for
ital status with annual mailed questionnaires through June
, 2006.
aboratory methods. Blood samples were obtained after
n overnight fast; serum and plasma were separated and
tored frozen at 70° C. Total cholesterol and triglyceride
evels were measured using an ABA-200 Biochromatic
nalyzer (Abbott Laboratories, Irving, Texas). High-
ensity lipoprotein was measured after precipitation of other
ipoproteins with heparin and manganese chloride. Low-
ensity lipoprotein was estimated using the Friedewald
ormula (34). Fasting plasma glucose levels were obtained in
he morning after an overnight fast and were measured by
he glucose oxidase method. In 2006, the Elecsys 2010
ystem (Roche Diagnostics, Indianapolis, Indiana) was used
or analysis of TnT using the Elecsys Troponin T sandwich
mmunoassay (measurable range 0.010 to 25.00 ng/ml) (35)
nd NT-proBNP using the Elecsys proBNP sandwich
mmunoassay (measurable range 5 to 35,000 pg/ml) (36,37)
n plasma that had been stored at 70°C. For TnT, the
anufacturer has reported an interassay coefficient of vari-
tion of 10% at 0.03 ng/ml (35). Intra-assay and interassay
oefficients of variation at various concentrations of NT-
roBNP were as follows: at 175 pg/ml, 2.7% and 3.2%,
espectively; at 355 pg/ml, 2.4% and 2.9%; at 1,068 pg/ml,
.9% and 2.6%; and at 4,962 pg/ml, 1.8% and 2.3% (36).
efinition of end points. The primary outcome was all-
ause mortality; the secondary end point was fatal CVD.
eath certificates were obtained for decedents and coded by
certified nosologist using the International Classification
f Disease–9th Revision criteria. The CVD death included
Abbreviations
and Acronyms
AUC  area under the
receiver-operator
characteristic curve
BMI  body mass index
BUN  blood urea nitrogen
CHD  coronary heart
disease
CVD  cardiovascular
disease
HR  hazard ratio
NT-proBNP  N-terminal
pro-B-type natriuretic
peptide
ROC  receiver-operator
characteristic
TnT  troponin Teaths assigned codes 390 through 459. Prevalent coronary
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TnT and NT-proBNP Predict Mortality August 5, 2008:450–9eart disease (CHD) was defined as a history of physician-
iagnosed myocardial infarction or coronary revasculariza-
ion. Prevalent CVD was defined as a history of CHD or
troke.
tatistical analysis. Continuous variables are presented as
eans  standard deviation, and dichotomous variables as
ercentages. Participants were divided into groups based on
nT levels: undetectable (n 917) and detectable (n 39).
hose with detectable levels were further divided into 2
roups: low (0.03 ng/ml) and high (0.03 ng/ml), cor-
esponding to the cut point suggested by current clinical
uidelines, which recommend that TnT levels greater than
he 99th percentile of a healthy population, in which
mprecision is10% (0.03 ng/ml), are considered abnormal
38). Participants were also grouped by NT-proBNP level
nto low (450 pg/ml, n  758) and high (450 pg/ml,
 199). This cut point corresponds to the recommended
ecision threshold for the general age group represented in
he Rancho Bernardo Study (36). Differences in baseline
aseline Characteristics of the Study Population
Table 1 Baseline Characteristics of the Study Population
TnT*
Variable Undetectable (n  917) Detectable (n
Age, yrs 76.3 8.4 83.5 8
Male gender, % 38 62
Cardiovascular risk factors
Hypertension, % 66 77
Heart rate, beats/min 66 10 64 9
Systolic BP, mm Hg 138 21 140 1
Diastolic BP, mm Hg 74 9 69 1
Current smoking, % 4 0
Ever smoked, % 54 64
Diabetes, % 11 26
Pre-existent disease, %
MI 11 28
CHD 15 38
Stroke 6 8
CVD 18 44
Medication use, %
Aspirin 42 31
Lipid-lowering 18 18
Nutrition and activity
Body mass index, kg/m2 25.4 4.1 24.7 3
Exercise 3/week, % 74 62
Alcohol 3/week, % 49 46
Laboratory values
Fasting glucose, mg/dl 103 20 112 3
BUN,† mg/dl 17 23
CrCl, ml/min 63 23 44 2
Total cholesterol, mg/dl 206 36 200 4
Triglycerides,† mg/dl 108 119
HDL cholesterol,† mg/dl 58 51
LDL cholesterol, mg/dl 121 32 117 3
NT-proBNP,† pg/ml 164 863
Detectable troponin, % N/A N/A
For troponin groups, detectable is 0.01 ng/ml; for NT-proBNP groups, low is 450 pg/ml; high
BP  blood pressure; BPM  beats per minute; BUN  blood urea nitrogen; CHD  coronary heart dise
DL  low-density lipoprotein; MI  myocardial infarction; NT-proBNP  N-terminal pro-B-type natriureticevels of risk factors and clinical characteristics between
articipants with and without detectable TnT or high
T-proBNP were analyzed with t tests and chi-square
ests; the Fisher exact test was used as appropriate. High-
ensity lipoprotein (HDL), triglycerides, blood urea nitro-
en (BUN), and NT-proBNP were not normally distrib-
ted and were log transformed for analyses; geometric
eans are reported. The association between NT-proBNP
nd age was examined using Spearman rank-order correla-
ion. The NT-proBNP levels and creatinine clearance levels
ere compared in participants with undetectable, low, and
igh TnT levels using analysis of variance and Tukey
ost-hoc tests. Multivariate covariates of elevated TnT and
T-proBNP were identified by logistic regression including
ariables with significant univariate associations; covariates
hat remained significant at p  0.05 were retained in the
nal model. Multivariate Cox proportional hazards regres-
ion models were used to determine the association of TnT
nd/or NT-proBNP with all-cause and CVD mortality.
NT-proBNP*
) p Value Low (n  758) High (n  199) p Value
0.001 74.9 8.2 82.8 6.6 0.001
0.003 40 37 0.44
0.14 61 85 0.001
0.26 66 9 65 11 0.67
0.65 136 19 147 25 0.001
0.013 74 9 72 11 0.058
0.40 4 4 0.97
0.20 54 56 0.58
0.018 11 14 0.36
0.003 8 25 0.001
0.001 12 30 0.001
0.73 5 12 0.001
0.001 15 37 0.001
0.19 42 37 0.25
0.96 19 13 0.037
0.30 25.6 4.1 24.4 4.1 0.001
0.086 76 62 0.001
0.69 49 48 0.76
0.076 104 21 104 21 0.90
0.001 17 19 0.001
0.001 66 23 48 18 0.001
0.28 208 36 199 38 0.002
0.35 111 103 0.088
0.012 57 58 0.67
0.48 123 32 114 34 0.001
0.001 112 970 0.001
N/A 2 15 0.001
0 pg/ml. †Geometric mean. 39
.3
8
1
.9
0
4
5
9
is 45
ase; CrCl  creatinine clearance; CVD  cardiovascular disease; HDL  high-density lipoprotein;
peptide; TnT  troponin T.
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August 5, 2008:450–9 TnT and NT-proBNP Predict Mortalityesults were expressed as hazard ratios (HRs) with 95%
onfidence intervals (CIs). For each analysis, 3 sequential
ox regression models were run. Model 1 adjusted for age
nd gender. For Model 2, life-style, risk factor, and labo-
atory covariates from Table 1 were analyzed, and univariate
redictors of all-cause mortality were identified if significant
t p  0.10. This process yielded age, gender, hypertension,
MI, heart rate, systolic blood pressure, diastolic blood
ressure, diabetes, physical activity, BUN, eCrCl, and
ogHDL, low-density lipoprotein, and total cholesterol as
otential predictors. Backward stepwise Cox regression
nalysis was performed using these 14 covariates; those that
emained significant at p 0.05 (age, gender, systolic blood
ressure, BMI, heart rate, physical activity, eCrCl, and total
holesterol) were retained in the final Model 2. Forward
tepwise analysis yielded the same 8 covariates. The influ-
nce of prevalent CHD was tested by adjusting for a history
f CHD in Model 3, and also by excluding those with
HD at baseline and repeating Models 1 and 2. Partici-
ants who were alive were censored at the date of their last
ollow-up. For survival analyses with CVD death as the
utcome, subjects who died of non-CVD causes were
ensored at date of death.
Kaplan-Meier plots were constructed to compare survival
n groups with detectable versus undetectable TnT and high
ersus low NT-proBNP. For analyzing the combination of
nT and NT-proBNP, 3 additional categories were de-
ned: high NT-proBNP with detectable TnT (n  27);
igh NT-proBNP but undetectable TnT (n  171); and
ow NT-proBNP (with any TnT level, n  758). Those
ith low NT-proBNP were grouped together regardless of
nT level because of the low number of participants with
he combination of low NT-proBNP and detectable TnT
n  12). All variables were treated as continuous variables
xcept gender, hypertension, diabetes, history of CHD,
moking status, physical activity, and alcohol consumption,
hich were treated as dichotomous variables. Framingham
isk scores were calculated based on published algorithms
39). Participants were classified into groups based on 3
ramingham risk categories (low, moderate, or high risk);
Rs for all-cause mortality within each Framingham risk
ategory, stratified by TnT or NT-proBNP level, were
alculated using Cox regression analysis, with the low
ramingham risk low TnT/NT-proBNP as the reference
roup. Receiver-operator characteristic (ROC) curves were
onstructed to evaluate the incremental benefit of TnT or
T-proBNP, when combined with the Framingham risk
core, for predicting all-cause mortality or CVD death.
reas under the receiver-operator characteristic curves
AUCs) were calculated and subsequent models were com-
ared using the Delong-Delong Clarke-Pearson method
40). Interactions of biomarkers by gender were tested for all
odels, and none were found. A 2-tailed p  0.05 was
onsidered statistically significant. Data were analyzed using
PSS 12.0 (SPSS Inc., Chicago, Illinois) and Analyse-it
2.08 (Leeds, England, United Kingdom).esults
aseline characteristics. Baseline demographic, clinical,
nd laboratory characteristics of the study population by
T-proBNP and TnT groups are shown in Table 1. At
aseline, the mean age of the 957 adults was 77 years (range
0 to 97 years); 39% were men. Overall, 12% of the
opulation had diabetes mellitus, 66% had hypertension,
nd 16% had CHD. Over a median follow-up of 6.8 years
interquartile range 5.9 to 7.4 years, maximum 9.2 years),
20 deaths occurred; 42% were attributed to CVD.
etectable TnT. The TnT levels were detectable in 4.1%
f the population and ranged from 0.010 to 0.061 ng/ml.
ompared with participants with undetectable TnT levels,
hose with detectable TnT were older and more likely to be
ale, hypertensive, and diabetic. They also had higher BUN
nd NT-proBNP levels, lower HDL cholesterol levels, and
oorer renal function as estimated by creatinine clearance
Table 1). Across the 3 categories of TnT levels (undetect-
ble, detectable but0.03 ng/ml, and0.03 ng/ml), higher
nT was associated with higher NT-proBNP levels and
educed creatinine clearance (Fig. 1).
Most participants with detectable TnT levels did not have a
istory of known CHD or CVD, even though such a history
as more common in this group than in those without
etectable levels (Fig. 2A). In multivariate analysis, covariates
f having detectable TnT were male gender, lower creatinine
learance, and higher NT-proBNP levels (Table 2).
levated NT-proBNP levels. The NT-proBNP levels
ere higher in women than in men (207 pg/ml vs. 136
g/ml, p  0.001), and increased with age (r  0.56, p 
.001). Like those with detectable TnT levels, participants
Figure 1 NT-proBNP Levels and Creatinine
Clearance Levels by Troponin T Category
Troponin T categories: undetectable, n  917; low, n  30; high, n  9.
Boxes depict interquartile range, and whiskers represent 10th and 90th per-
centiles. *p  0.001 versus undetectable. †p  0.001 versus undetectable
and p  0.03 versus low. ‡p  0.001 versus low and p  0.02 versus high.
NT-proBNP  N-terminal pro-B-type natriuretic peptide.
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TnT and NT-proBNP Predict Mortality August 5, 2008:450–9ith higher NT-proBNP levels (450 pg/ml) were older
han those with lower levels, had a higher prevalence of
ypertension and CHD at baseline, and were more likely to
ave detectable TnT. They also had lower BMI, total and
ow-density lipoprotein cholesterol, and creatinine clearance
evels; had higher systolic blood pressure and BUN; and
ere less likely to be taking lipid-lowering medications or to
xercise regularly (Table 1).
Only 30% of those with elevated NT-proBNP levels had
history of CHD at baseline (Fig. 2B). In multivariate
nalysis, predictors of elevated NT-proBNP levels were age
70 years, higher systolic blood pressure, history of stroke,
ailure to exercise at least 3 times per week, lower creatinine
Figure 2 Prevalence of Baseline CHD and Distribution of TnT a
(A) Prevalence of baseline coronary heart disease (CHD) in participants with unde
detectable levels (right). (B) Prevalence of baseline CHD in participants with low v
(right). NT-proBNP  N-terminal pro-B-type natriuretic peptide; prior CHD  myocalearance, and detectable troponin level (Table 2). (utcomes. TNT AND RISK OF DEATH. Of the 220 partici-
ants who died during follow-up, 11% had detectable TnT
evels, compared with only 2% of survivors (p  0.001).
mong all study participants, a detectable TnT level was
ssociated with increased risk of all-cause death and of
VD death after adjusting for age and gender (Table 3,
odel 1), and after further adjusting for other risk factors
Model 2). Further adjusting for the presence of CHD at
aseline did not materially alter the findings (Model 3).
hen the analysis was restricted to the 806 participants
ithout known CHD at baseline, detectable TnT remained
significant predictor of all-cause death. Figure 3 shows
aplan-Meier survival curves by TnT group in all subjects
-proBNP
le and detectable TnT levels (left), and distribution of TnT among those with
high NT-proBNP levels (left), and distribution of NT-proBNP among all subjects
farction or revascularization; TnT  troponin T.nd NT
tectab
ersus
rdial inFig. 3A) and in subjects without CHD at baseline (Fig.
3
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August 5, 2008:450–9 TnT and NT-proBNP Predict MortalityB); in both cases, mortality was higher for subjects with
etectable TnT levels.
T-PROBNP AND RISK OF DEATH. Forty percent of the 220
articipants who died during follow-up had elevated NT-
roBNP levels, compared with 15% of survivors (p  0.001).
fter adjusting for age and gender, elevated NT-proBNP
evels predicted all-cause and CVD mortality (Table 3). After
urther adjusting for other risk factors, NT-proBNP level
emained a strong predictor of all-cause and of CVD mortality.
n the 806 participants without baseline CHD, higher NT-
roBNP levels were still significantly predictive of mortality,
ven after adjusting for other risk factors. Mortality was higher
n subjects with NT-proBNP 450 pg/ml (Fig. 3C) even
ultivariate Predictorsf Detectable TnT or Elevated NT-proBNP
Table 2 Multivariate Predictorsof Detectable TnT or Elevated NT-proBNP
Risk Determinants Odds Ratio (95% CI) p Value
Risk determinants for detectable TnT
Male gender 5.41 (2.50–11.6) 0.001
CrCl* 0.45 (0.26–0.78) 0.004
log (NT-proBNP)* 3.47 (2.31–5.21) 0.001
Risk determinants for elevated NT-proBNP
Age 70 yrs 3.58 (1.76–7.27) 0.001
Systolic blood pressure* 1.54 (1.29–1.83) 0.001
History of stroke 3.43 (1.39–8.43) 0.007
Exercise 3 times per week 1.93 (1.31–2.83) 0.001
CrCl* 0.49 (0.38–0.63) 0.001
Detectable TnT 7.49 (3.32–16.9) 0.001
 953 in TnT model, and n  949 in NT-proBNP model. *Per SD increase.
CI  confidence interval; other abbreviations as in Table 1.
ultivariate Models for Predicting All-Cause and CVD Mortality
Table 3 Multivariate Models for Predicting All-Cause and CVD
All-Cause Mortality
All Subjects
(n  220 Deaths)
Baseline CH
(n  157
HR (95% CI) p Value HR (95% CI)
TnT* (dichotomous)
Model 1 2.25 (1.44–3.52) 0.001 2.20 (1.23–3.93
Model 2 2.06 (1.29–3.28) 0.003 2.38 (1.30–4.36
Model 3 1.87 (1.16–3.00) 0.010 N/A
NT-proBNP† (continuous)
Model 1 2.29 (1.70–3.09) 0.001 2.00 (1.38–2.88
Model 2 1.85 (1.36–2.52) 0.001 1.74 (1.19–2.55
Model 3 1.67 (1.21–2.29) 0.002 N/A
TnT* and NT-proBNP†
Model 1
TnT 1.69 (1.06–2.68) 0.026 1.75 (0.96–3.18
NT-proBNP 2.09 (1.54–2.84) 0.001 1.82 (1.25–2.65
Model 2
TnT 1.63 (1.00–2.66) 0.052 1.94 (1.03–3.66
NT-proBNP 1.68 (1.22–2.31) 0.001 1.54 (1.04–2.29
Model 3
TnT 1.59 (0.97–2.59) 0.065 N/A
NT-proBNP 1.53 (1.10–2.12) 0.011 N/A
Hazard ratios for TnT are for detectable versus undetectable levels. †Hazard ratios for NT-proBNP
ass index, heart rate, physical activity, total cholesterol, and creatinine clearance. Model 3, Model 2 
CI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.hen the analysis was restricted to those participants without
nown CHD at baseline (Fig. 3D).
ombination of TnT and NT-proBNP for predicting
eath. When both TnT and NT-proBNP were included in
he Cox regression model, each was independently predic-
ive of all-cause mortality even after excluding participants
ith known CHD at baseline (Table 3).
Participants with both high NT-proBNP levels and
etectable TnT levels had an increased risk of mortality
Fig. 4A) (adjusted HR for high NT-proBNP and detect-
ble TnT vs. low NT-proBNP and any TnT: 3.20, 95% CI:
.91 to 5.38). This association held true in analyses re-
tricted to subjects without baseline CHD (Fig. 4B) (ad-
usted HR: 3.05, 95% CI: 1.52 to 6.12) and was even
tronger when the outcome was limited to cardiovascular
eaths (adjusted HR: 3.87, 95% CI: 1.83 to 8.15).
ramingham risk score stratification. An increased risk of
eath among participants with detectable TnT was evident in
ow-risk, intermediate-risk, and high-risk individuals, as clas-
ified by Framingham risk score (Fig. 5A). Use of TnT to
tratify low-risk and intermediate-risk individuals resulted in
eclassification of 4% of participants into a high-risk group,
ased on TnT detectability. Also, TnT significantly improved
he AUC for the prediction of all-cause mortality and for CVD
eath compared with the Framingham risk score alone (AUC
.625 vs. 0.575, p 0.011 for all-cause mortality and 0.668 vs.
.597, p  0.017 for CVD death).
Similarly, elevated NT-proBNP levels were associated
ith an increased risk of death in each Framingham risk
lity
CVD Mortality
luded
s)
All Subjects
(n  92 Deaths)
Baseline CHD Excluded
(n  52 Deaths)
p Value HR (95% CI) p Value HR (95% CI) p Value
0.008 2.25 (1.17–4.32) 0.015 1.26 (0.39–4.09) 0.71
0.005 2.06 (1.03–4.12) 0.040 1.42 (0.42–4.86) 0.58
1.61 (0.79–3.28) 0.19 N/A
0.001 3.50 (2.19–5.58) 0.001 2.41 (1.25–4.65) 0.009
0.004 2.51 (1.55–4.08) 0.001 1.85 (0.94–3.64) 0.078
1.93 (1.17–3.19) 0.011 N/A
0.067 1.45 (0.74–2.87) 0.28 0.88 (0.26–2.98) 0.84
0.002 3.27 (2.02–5.30) 0.001 2.45 (1.25–4.82) 0.009
0.041 1.41 (0.68–2.94) 0.36 1.05 (0.29–3.80) 0.94
0.033 2.34 (1.41–3.89) 0.001 1.83 (0.90–3.72) 0.093
1.33 (0.64–2.74) 0.45 N/A
1.84 (1.10–3.08) 0.020 N/A
1 unit log increase. Model 1, age and gender. Model 2, age, gender systolic blood pressure, bodyMorta
D Exc
Death
)
)
)
)
)
)
)
)
are per
baseline CHD.
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TnT and NT-proBNP Predict Mortality August 5, 2008:450–9roup (Fig. 5B). The use of NT-proBNP would have
eclassified 17% of participants as high risk, based on
T-proBNP450 pg/ml. The addition of NT-proBNP to
he Framingham risk score improved the AUC for predic-
ion of all-cause mortality from 0.575 to 0.704, and for
VD death from 0.597 to 0.725 (p  0.001 for each).
Similar results were seen when CVD death was used as
he primary outcome measure (data not shown).
iscussion
n this cohort, apparently healthy community-dwelling
dults with minimally detectable TnT were at increased risk
f death. Elevated NT-proBNP levels also independently
redicted death in this cohort. The predictive ability was
mproved by incorporating both TnT and NT-proBNP,
nd the prognostic value of each biomarker persisted for
Figure 3 Kaplan-Meier Survival Plots by TnT or NT-proBNP Leve
(A) Survival in participants with undetectable versus detectable TnT levels. n  19
and n  23 deaths in the detectable TnT group (of 39 participants with detectable
analysis limited to those participants without baseline coronary heart disease (CH
able TnT) and n  13 deaths in the detectable TnT group (of 24 participants with
pg/ml) NT-proBNP levels. n  132 deaths in the low NT-proBNP group (of 758 par
participants with high NT-proBNP). (D) Survival in participants with low versus high
 106 deaths in the low NT-proBNP group (of 667 participants with low NT-proBNP
proBNP). Abbreviations as in Figure 2.ears after initial measurement. aCurrent guidelines recommend that TnT levels 0.03
g/ml be considered abnormal (38). However, we have
hown that individuals with any detectable TnT level, even
hose lower than this cut point, have clinical features
uggestive of poor health, including higher NT-proBNP
evels and poorer renal function. This is in agreement with
he findings of Wallace et al. (12), who also noted that
ndividuals with detectable TnT tended to have significant
omorbidity. Importantly, in the present study more than
0% of those with detectable TnT did not have known prior
eart disease, and the prognostic ability of TnT was
ndependent of other CHD risk factors. Thus, cardiac TnT
robably reflects subclinical heart disease in adults without
nown CHD. When analysis was limited to the subgroup of
articipants without prior CHD, the strength of the asso-
iations between detectable TnT or elevated NT-proBNP
ths in the undetectable TnT group (of 917 participants with undetectable TnT)
(B) Survival in participants with undetectable versus detectable TnT levels, with
143 deaths in the undetectable TnT group (of 781 participants with undetect-
able TnT). (C) Survival in participants with low (450 pg/ml) versus high (450
ts with low NT-proBNP) and n  88 deaths in the high NT-proBNP group (of 199
BNP levels, with analysis limited to those participants without baseline CHD. n
n  51 deaths in the high NT-proBNP group (of 139 participants with high NT-ls
6 dea
TnT).
D). n 
detect
ticipan
NT-pro
) andnd all-cause mortality was not materially changed, suggest-
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August 5, 2008:450–9 TnT and NT-proBNP Predict Mortalityng that TnT and NT-proBNP are predictive even in an
pparently heart disease–free population.
The prevalence of detectable TnT in the Rancho Ber-
ardo cohort was 4.1%, higher than the prevalence of 0.7%
stimated from the population-based Dallas Heart Study
12). This difference likely reflects the younger age of the
allas cohort. Few studies have reported the clinical signif-
cance of minimally elevated troponin levels. Wallace et al.
12) reported that the presence of measurable troponin
evels among the 3,557 subjects from the Dallas Heart
tudy was associated with a high-risk phenotype including
nderlying heart failure, left ventricular hypertrophy,
hronic kidney disease, or diabetes, but did not report on
ow the presence of a measurable troponin level affected
linical outcomes. The only prior study that has reported
inimally detectable troponin levels and outcomes in the
eneral population was based on registry data and in-
luded only men; in this study Zethelius et al. (13)
eported that cardiac troponin I predicted death and first
HD event over approximately 10 years of follow-up in
,203 elderly men, and this association was independent
f conventional risk factors.
The association of even minimally elevated TnT levels
ith mortality suggests that TnT is a marker of subclin-
cal myocardial damage. Plausible mechanisms for the
elease of detectable TnT in the blood include silent
schemia, microvascular disease, left ventricular strain,
mpaired subendocardial perfusion, endothelial dysfunc-
ion, apoptosis, oxidative stress injury, inflammation, or
ther undetermined factors leading to microscopic myo-
ardial cell necrosis or cellular membrane leak reflecting
ncreased myocyte permeability (41– 45). Until more
ensitive tests become available, the relatively low prev-
lence of detectable TnT levels in the community may
Figure 4 Kaplan-Meier Survival Plots by Combined TnT and NT-
(A) n  132 deaths in the high NT-proBNP/detectable TnT group, n  68 deaths
NT-proBNP group. (B) Analysis limited to those participants without baseline coron
n  40 deaths in the high NT-proBNP/undetectable TnT group, and n  10 deathsimit its utility as a screening agent. mIn contrast, natriuretic peptides have been shown to
redict cardiovascular disease in a variety of settings, includ-
ng apparently healthy individuals. The NT-proBNP cut
oint of 450 pg/ml, derived from the recommended deci-
ion threshold for older outpatients with shortness of
reath, also provided prognostic information in this
ommunity-based population of older adults. In the Fra-
ingham Offspring Study of 3,346 individuals with a mean
ge of 58 years, Wang et al. (29) found a 27% increased risk
f death for each 1-SD increment in log BNP levels during
.2 years of follow-up; higher BNP levels were also associ-
ted with increased risk of cardiovascular events, atrial
brillation, heart failure, and stroke or transient ischemic
ttack. Kistorp et al. (46) measured NT-proBNP levels in a
ommunity-based cohort of 626 Danish adults (mean age 68
ears) and reported a 43% increase in the adjusted risk of death
rom any cause per 1-SD increase in log NT-proBNP. These
esults are similar to the 39% increased risk of death per 1-SD
ncrease in log NT-proBNP reported in the present study.
igher NT-proBNP levels were also associated with the first
ajor cardiovascular event in the Danish cohort, in agreement
ith our finding of increased risk of cardiovascular death in
ndividuals with elevated NT-proBNP.
In the present study, the coexistence of both elevated
T-proBNP and a detectable troponin level was uncom-
on, but was associated with a 3.2-fold increased risk of
eath. The effects of NT-proBNP and TnT were indepen-
ent of each other, which is in accord with their differing
athophysiologic roles. It is likely that each marker identi-
es a distinct physiology, either of which confers increased
isk. It is plausible that the simultaneous presence of
ubclinical myocardial ischemia and increased left ventricu-
ar wall stretch portends an outcome worse than either
actor alone. Both NT-proBNP and TnT measurements
P Levels
high NT-proBNP/undetectable TnT group, and n  19 deaths in the low
art disease (CHD). n  106 deaths in the high NT-proBNP/detectable TnT group,
e low NT-proBNP group. Abbreviations as in Figure 2.proBN
in the
ary he
in thay prove clinically useful in identifying a high-risk popu-
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TnT and NT-proBNP Predict Mortality August 5, 2008:450–9ation with subclinical CVD in whom aggressive preventive
easures may be warranted. Further studies are needed to
valuate this possibility. Both TnT and NT-proBNP added
ignificantly to risk prediction by the Framingham score,
ith elevated levels of either marker predicting an increased
azard of death, irrespective of Framingham risk level.
lthough both biomarkers improved the AUC for predic-
ion of CVD death and all-cause mortality, NT-proBNP
aised the AUCs more than TnT. Elevated NT-proBNP is
lso more prevalent than detectable TnT, and is therefore
etter suited to screening.
tudy limitations. This study has several limitations.
ecause the Rancho Bernardo Study consists primarily of
iddle-class to upper-middle-class adults of European
ncestry, the results may not be generalizable to other
thnic and socioeconomic groups. Baseline CHD events
ere based on self-report of prior coronary revasculariza-
ion or of a physician diagnosis, which could have
Figure 5 Framingham Risk Score and Incremental Prognostic
Value of Troponin T or NT-proBNP for Predicting Death
Reference group in (A) is the group with low Framingham risk score (10%)
and undetectable troponin T. Reference group in (B) is the group with low Fra-
mingham risk scores and NT-proBNP 450 pg/ml. Framingham risk score was
calculated as low risk (10% risk of events over 10 years), moderate risk
(10% to 20%), and high risk (20%). Abbreviations as in Figure 2.esulted in misclassification. However, at an earlier Ran-ho Bernardo study visit, 85% of reported cardiovascular
vents were confirmed in the 30% subset that had medical
ecords permitting validation. Also, this study had small
umbers of individuals with measurable TnT, limiting
ur ability to identify all important predictors of detect-
ble TnT levels and our power to detect significant
ssociations with CVD mortality after excluding partic-
pants with baseline CHD. Nonetheless, we were able to
how a significant association for both TnT and NT-
roBNP with all-cause mortality even after excluding
articipants with baseline CHD. In this case both TnT
nd NT-proBNP remained independent predictors of death.
onclusions
pparently healthy community-dwelling adults with mini-
ally detectable TnT levels or elevated NT-proBNP levels
re at an increased risk of death. Those with both TnT and
T-proBNP elevations are at even higher risk, and the
ncreased risk adds significantly to the Framingham risk
core prediction and persists for years. Further studies are
eeded to determine whether early interventions in individ-
als with elevated TnT or NT-proBNP levels could help
mprove long-term outcomes.
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